ACACA and metabolic dysfunction-associated steatohepatitis: Our studies indicate that other compounds, such as ACC1 (ACACA) inhibitors (59), that are currently in clinical trials for NASH could also ameliorate fibrosis development and offer an entirely new class of drugs for kidney dysfunction.